The ASAP2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This loss-of-function model disrupts the ASAP2 gene across a heterogeneous pool of cells, eliminating the need for clonal isolation while enabling gene function studies in a cancer-relevant context. This approach provides a cost-effective and rapid system for investigating gene function without monoclonal selection.
The A-549 cell line, originating from a 58-year-old Caucasian male with lung carcinoma, serves as a well-established model for non-small cell lung cancer (NSCLC).
These adherent epithelial cells retain key features of lung adenocarcinoma, including KRAS mutations, and are widely used to study cancer cell invasion, metastasis, and signal transduction mechanisms. A-549 cells are extensively characterized for their constitutive activation of the RAS-RAF-MEK-ERK cascade, making them an ideal background for studying pathways that intersect with RAS signaling.
ASAP2 is a multidomain Arf GTPase-activating protein that regulates membrane trafficking and actin cytoskeleton remodeling. It is activated by upstream signals from EGFR, HGF, and integrins, and inactivates Arf1 and Arf6 GTPases to control PIP2 levels, paxillin recruitment, and focal adhesion kinase (FAK) activity.
ASAP2 directly interacts with Src kinase, paxillin, cortactin, and Crk, forming complexes that orchestrate focal adhesion turnover and cell migration. In the EGFR-Src-ASAP2-Arf6-Rac1-paxillin signaling axis, ASAP2 couples receptor activation to actin polymerization at the cell periphery. Its GAP activity is regulated by membrane phospholipids such as phosphatidic acid, integrating lipid cues with cytoskeletal dynamics.
Knockout of ASAP2 in A-549 cells is expected to disrupt Arf-dependent membrane recycling and focal adhesion dynamics, leading to impaired cell migration and reduced invasive capacity.
This phenotype makes the model highly relevant for dissecting the molecular mechanisms of NSCLC metastasis and for evaluating the role of ASAP2 in tumor cell motility and extracellular matrix interaction. Additionally, ASAP2 loss may alter the cellular response to EGFR inhibitors or integrin antagonists, providing a platform for investigating therapeutic combinations targeting adhesion and growth factor signaling.
This polyclonal knockout model is ideal for investigating ASAP2 function in lung cancer migration using wound healing and transwell invasion assays. Immunofluorescence for actin and paxillin reveals changes in adhesion structures, while Arf-GTP pull-down and western blotting quantify GTPase activation.
Co-immunoprecipitation enables mapping of ASAP2 interactions with Src and cortactin. Furthermore, the cells support CRISPR loss-of-function screens, rescue experiments with wild-type or mutant ASAP2 constructs, and high-content imaging of adhesion dynamics. For further information or custom inquiries, contact Ascent Research.
